Literature DB >> 12877104

Reduction or elimination of postoperative pain medication after mastectomy through use of a temporarily placed local anesthetic pump vs. control group.

J E Morrison, V R Jacobs.   

Abstract

OBJECTIVE: We evaluated the efficacy of a temporarily placed porous catheter with continuous application of a local anaesthetic(ON-Q( by l-Flow-Corp., Lake Forest, CA, USA) post mastectomy vs. patients without this device regarding postoperative need for opioid medication.
MATERIAL AND METHODS: At Fayette Medical Center, Alabama, a retrospective evaluation of all consecutive mastectomies (n = 49) within a five-year-period from 1/1997-12/2001 and statistical analysis regarding postoperative need for opioids was performed. The ON-Q pain management pump with continuous 0.25% Sensorcaine (Bupivacaine and Epinephrine) application for about 72 h (n- 22) was compared vs. a control group without pain management pump (n- 27).
RESULTS: There were no statistical significant differences regarding patient demographics in both groups. Patients in the ON-Q group with no need of postoperative opioid pain medication were: 18.2 vs. 3.7 % (P - 0.1), no need for opioids after postoperative day 1: 68.2% vs. 11.1 % (P 0.001), total opioids usage in dose equivalents (DE): 1.25 vs. 3.36 DE (-62.8%) (P-0.016), opioids usage postoperative day 1: 0.65 vs. 1.82 DE (-64.6%) (P - 0.016),opioids usage postoperative day 2: 0.24 vs. 0.75 DE (-68.4%)(P - 0.011). The length of stay in hospital was 2.35 vs. 2.93 days(n.s.), and postoperative stay in PACU: 384 vs. 43.3 min (n. s.).OR time for placement of catheter and pump is only slightly increased. No complications occurred.
CONCLUSION: Use of an ON-Q pain management pump could significantly reduce or even eliminate postoperative need for opioids analgesics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12877104     DOI: 10.1055/s-2003-40364

Source DB:  PubMed          Journal:  Zentralbl Gynakol        ISSN: 0044-4197


  5 in total

1.  Cost-effectiveness analysis of levobupivacaine 0.5 %, a local anesthetic, infusion in the surgical wound after modified radical mastectomy.

Authors:  Lourdes Ferreira Laso; Amanda López Picado; Fernando Antoñanzas Villar; Laura Lamata de la Orden; Mar Ceballos Garcia; Carolina Ibañez López; Lorena Pipaon Ruilope; Felix Lamata Hernandez; Cesar Valero Martinez; Felipe Aizpuru; Roberto Hernandez Chaves
Journal:  Clin Drug Investig       Date:  2015-09       Impact factor: 2.859

2.  The ON-Q pain management system in elective gynecology oncologic surgery: Management of postoperative surgical site pain compared to intravenous patient-controlled analgesia.

Authors:  Dawn Chung; Yoo Jin Lee; Mi Hyun Jo; Hyun Jong Park; Ga Won Lim; Hanbyoul Cho; Eun Ji Nam; Sang Wun Kim; Jae Hoon Kim; Young Tae Kim; Sunghoon Kim
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

3.  A randomized trial of bupivicaine pain pumps to eliminate the need for patient controlled analgesia pumps in primary laparoscopic Roux-en-Y gastric bypass.

Authors:  Daniel R Cottam; Barry Fisher; James Atkinson; Daniel Link; Peter Volk; Clifford Friesen; Daniel Link; Brian Grace; Robin Trovar
Journal:  Obes Surg       Date:  2007-05       Impact factor: 4.129

Review 4.  Consensus Review of Optimal Perioperative Care in Breast Reconstruction: Enhanced Recovery after Surgery (ERAS) Society Recommendations.

Authors:  Claire Temple-Oberle; Melissa A Shea-Budgell; Mark Tan; John L Semple; Christiaan Schrag; Marcio Barreto; Phillip Blondeel; Jeremy Hamming; Joseph Dayan; Olle Ljungqvist
Journal:  Plast Reconstr Surg       Date:  2017-05       Impact factor: 5.169

5.  Study protocol for a double blind, randomised, placebo-controlled trial of continuous subpectoral local anaesthetic infusion for pain and shoulder function following mastectomy: SUB-pectoral Local anaesthetic Infusion following MastEctomy (SUBLIME) study.

Authors:  R Langford; I Brown; J Vickery; K Mitchell; C Pritchard; S Creanor
Journal:  BMJ Open       Date:  2014-09-30       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.